Exploring the therapeutic potential of rosemary compounds against Alzheimer’s disease through GC-MS and molecular docking analysis
In Silico Pharmacology · 17.07.2024 · 12 (2)
DOI: 10.1007/s40203-024-00238-9 ↗Kurz gefasst
Fachartikel in der Zeitschrift In Silico Pharmacology, online erschienen am 17.07.2024. Verfasst von Anjali Singh und 5 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Biosciences, Institute of Biosciences and Technology, Shri Ramswaroop Memorial University, Lucknow-Dewa Road, Barabanki, Uttar Pradesh 225…. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Themen: Demenz
Abstract (Originalsprache)
Alzheimer's disease (AD) is an age-related neurodegenerative disorder that is the leading cause of dementia in elderly individuals. Currently, there is no permanent treatment option available for this disorder, and the existing drug regimens are associated with limited effectiveness and side effects. To evaluate the neuroprotective effect of rosemary compounds, an extensive study was started with gas chromatography-mass spectrometry (GC-MS) analysis. GC-MS was performed to study the composition of rosemary essential oil and a total of 120 volatile compounds were identified. The 36 compounds from GC-MS data of rosemary essential oil having > 1% concentration in the oil were selected along with 3 already reported well-known non-volatile compounds of rosemary. se39 bioactive natural compounds of rosemary were docked against ACE, BACE1, GSK3, and TACE proteins, which are involved in AD progression. The top 3 compounds against each target protein were selected based on their binding energies and a total of 6 compounds were found as best candidates to target the AD; α Amyrin, Rosmanol, Androsta-1,4-dien-3-one,16,17-dihydroxy-(16.beta.,17.beta), Benzenesulfonamide,4-methyl-N-(5-nitro-2-pyridinyl), Methyl abietate, and Rosmarinic acid were the best compounds. The binding energy of α-Amyrin, Rosmanol, and Androsta-1,4-dien-3-one,16,17-dihydroxy-(16.beta.,17.beta) to ACE target is -10 kcal/mol, -9.3 kcal/mol, and - 9.3 kcal/mol, respectively. The best binding affinity was shown by complexes formed between GSK3-α-Amyrin (-9.1 kcal/mol), BACE1- α-Amyrin (-9.9 kcal/mol), and TACE- Benzenesulfonamide,4-methyl-N-(5-nitro-2-pyridinyl) (-9.1 kcal/mol). The comparative analysis between known inhibitors/ drugs of target proteins and the rosemary compound that shows the highest binding affinity against each protein also revealed the higher potential of rosemary natural compounds in terms of binding energy. The drug-likeliness properties like Lipinski's rule of five and the ADME/T analysis of top-selected compounds were screened through PkCSM and Deep-PK tools. The findings from this study suggested that rosemary compounds have the potential as a therapeutic lead for treating AD. This kind of experimental confirmation can lead to novel drug candidates against the pharmacological targets of AD. Supplementary Information: The online version contains supplementary material available at 10.1007/s40203-024-00238-9.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Faculty of Biosciences, Institute of Biosciences and Technology, Shri Ramswaroop Memorial University, Lucknow-Dewa Road, Barabanki, Uttar Pradesh 225003 India.
- Department of Biosciences, Integral University, Kursi Road, Lucknow, Uttar Pradesh 226026 India.
- Chitkara College of Pharmacy, Chitkara University, Rajpura, Punjab 140401 India.
- Department of Bioengineering, Integral University, Kursi Road, Lucknow, Uttar Pradesh 226026 India.
Zitieren
APA
Singh, A., Singh, D., Tiwari, N., Mittal, P., Siddiqui, M. H., & Mittal, N. (2024). Exploring the therapeutic potential of rosemary compounds against Alzheimer’s disease through GC-MS and molecular docking analysis. In Silico Pharmacology, 12(2). https://doi.org/10.1007/s40203-024-00238-9
Vancouver
Singh A, Singh D, Tiwari N, Mittal P, Siddiqui MH, Mittal N. Exploring the therapeutic potential of rosemary compounds against Alzheimer’s disease through GC-MS and molecular docking analysis. In Silico Pharmacology. 2024;12(2). doi:10.1007/s40203-024-00238-9
BibTeX
@article{Singh2024,
author = {Singh, Anjali and Singh, Dhananjay and Tiwari, Neeraj and Mittal, Pooja and Siddiqui, Mohammed Haris and Mittal, Nishu},
title = {Exploring the therapeutic potential of rosemary compounds against Alzheimer’s disease through GC-MS and molecular docking analysis},
journal = {In Silico Pharmacology},
year = {2024},
volume = {12},
number = {2},
doi = {10.1007/s40203-024-00238-9}
}
EUVIMED